Evidence map›Paper›PMID 25861268›Full record

ReviewInternational journal of endocrinology2015

Application of berberine on treating type 2 diabetes mellitus.

Bing Pang, Lin-Hua Zhao, Qiang Zhou, Tian-Yu Zhao, Han Wang, Cheng-Juan Gu, Xiao-Lin Tong

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03378934 (A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention), which is not on this map. Cited by 114 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03378934 phase4recruitingnot on this mapstarted 2018, after this paper: background citation

A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention

TypeinterventionalSponsorPeking Union Medical College HospitalRan2018 to 2026Enrolled64ConditionsCoronary Artery Disease, Percutaneous Coronary InterventionArmsBerberine, Standard treatment, Aspirin, Clopidogrel
3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Berberine alleviates alcoholic liver diseaseactivating intestinal nuclear receptor subfamily 1 group D member 1.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Article
  7. Article
  8. Molecular landscape of Berberine's therapeutic potential in gastrointestinal disorders.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bing PangDepartment of Endocrinology, Guang'anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing 100054, China.
Lin-Hua ZhaoLaboratory of Molecular and Biology, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Beijing 100054, China.
Qiang ZhouDepartment of Digestion, Beijing Hospital of Traditional Chinese Medicine, Capital University of Medicine Sciences, Beijing 100010, China.
Tian-Yu ZhaoDepartment of Endocrinology, Guang'anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing 100054, China.
Han WangDepartment of Endocrinology, Guang'anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing 100054, China.
Cheng-Juan GuDepartment of Endocrinology, Guang'anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing 100054, China.
Xiao-Lin TongDepartment of Endocrinology, Guang'anmen Hospital of China, Academy of Chinese Medical Sciences, Beijing 100054, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional Chinese medicine (TCM) performs a good clinical practice and is showing a bright future in the treatment of diabetes mellitus (DM). TCM treatment has certain advantages of less toxicity and/or side effects, and herbs could provide multiple therapeutic effects. Berberine (BBR) is a classical natural medicine. In this review, we summarize the application of BBR in the treatment of DM from two aspects. First, modern pharmacological effects of BBR on glucose metabolism are summarized, such as improving insulin resistance, promoting insulin secretion, inhibiting gluconeogenesis in liver, stimulating glycolysis in peripheral tissue cells, modulating gut microbiota, reducing intestinal absorption of glucose, and regulating lipid metabolism. BBR is used to treat diabetic nephropathy (DPN), diabetic neuropathy (DN), and diabetic cardiomyopathy due to its antioxidant and anti-inflammatory activities. Second, the clinical application of BBR is reviewed, such as listing some clinical trials on the effectiveness and safety of BBR, explaining applicable stage and syndrome, the reasonable dose and dose formulation, and the toxicity and/or side effects. This review provides scientific evidence about BBR, as well as introducing some traditional Chinese medical theory and clinical experience, in order to guide clinician to use BBR more suitably and reasonably.

Identifiers

PMID25861268
PMCPMC4377488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.